Gilead to Test Inhaled Form of Anti-Covid Drug to Widen Its Use

Gilead Sciences Inc. said it plans to start human trials of an inhaled version of its anti-Covid-19 drug remdesivir, a move that could significantly expand its use if successful.

Remdesivir has been the go-to drug for treating hospitalized Covid-19 patients since U.S. regulators gave it an emergency use authorization in May, after a study showed it could speed recovery from the disease. A drawback is that it’s administered through daily infusions at a hospital over a course of five to ten days, significantly limiting use.

An inhaled version could allow Gilead to give the drug to a broader group of ...